Dihydropyridine compounds for treating or preventing metabolic disorders

Details for Australian Patent Application No. 2004272078 (hide)

Owner Synta Pharmaceuticals Corp.

Inventors Chen, Shoujun; Xia, Zhi-Qiang; Borella, Christopher; Sun, Lijun; Zhang, Shijie; Ono, Mitsunori; Wada, Yumiko; Foley, Kevin; Li, Hao; Koya, Keizo; Przewloka, Teresa; Zhou, Dan

Agent Davies Collison Cave

Pub. Number AU-A-2004272078

PCT Pub. Number WO2005/025507

Priority 60/502,353 10.09.03 US; 60/561,264 09.04.04 US

Filing date 10 September 2004

Wipo publication date 24 March 2005

International Classifications

A61K 31/4709 (2006.01) - Non-condensed quinolines containing further heterocyclic rings

A61K 31/47 (2006.01) - Quinolines

C07D 215/20 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/025507 Priority application(s): WO2005/025507

29 January 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004272081-Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents

2004272077-Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation